{"id":"bay-59-8862","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, Bay 59-8862 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism of action is associated with several potential benefits, including improved glycemic control and weight loss.","oneSentence":"Bay 59-8862 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:22.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00054314","phase":"PHASE2","title":"BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2002-03","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT01989884","phase":"PHASE2","title":"An Efficacy Study Of Ortataxel In Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-11","conditions":"Glioblastoma","enrollment":45},{"nctId":"NCT00044525","phase":"PHASE2","title":"Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-04","conditions":"Breast Neoplasms, Breast Cancer, Metastatic","enrollment":82},{"nctId":"NCT00044564","phase":"PHASE2","title":"Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-12","conditions":"Carcinoma, Renal Cell","enrollment":54},{"nctId":"NCT00044551","phase":"PHASE2","title":"Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-02","conditions":"Lymphoma, Non-Hodgkin","enrollment":29},{"nctId":"NCT00044538","phase":"PHASE2","title":"Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-12","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":102},{"nctId":"NCT00039169","phase":"PHASE2","title":"BAY 59-8862 in Treating Patients With Advanced Kidney Cancer","status":"UNKNOWN","sponsor":"Theradex","startDate":"2001-12","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT00039156","phase":"PHASE2","title":"BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Theradex","startDate":"2002-01","conditions":"Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bay 59-8862","genericName":"Bay 59-8862","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bay 59-8862 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}